Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.

Huang H, Hu C, Liu F, Ji F, Fu Y, Cao M

British journal of anaesthesia21 Nov 2024Cited by 14 (Europe PMC)

PMID39578156DOI10.1016/j.bja.2024.10.013PepBankPUB-39578156

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studySafety outcome
In FAERS semaglutide reports, older age was linked to lower odds of impaired gastric emptying.
In plain wordsIn semaglutide reports, older age was linked to lower odds of impaired stomach emptying.
Peptide
Semaglutide
Outcome
DecreaseAge association with impaired gastric emptying
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Age odds ratio
0.96 ratio
semaglutide
Lower confidence limit
0.94 ratio
95% CI
Upper confidence limit
0.97 ratio
95% CI
Source sentences
Summary
Dulaglutide (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.94-1.00, P=0.033) and semaglutide (OR 0.96, 95% CI 0.94-0.97, P=0.001) showed lower IGE risk with older age.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
Report a problemFND-3957815602
02HumanObservational studySafety outcome
In FAERS semaglutide reports, median time to impaired gastric emptying onset was 40.5 days after treatment initiation.
In plain wordsIn semaglutide reports, impaired stomach emptying began a median of 40.5 days after treatment started.
Peptide
Semaglutide
Outcome
Not applicableTime to impaired gastric emptying onset
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Median onset
40.5 days
semaglutide
Source sentences
Summary
Median onset times ranged from 40.5 days (semaglutide) to 107.5 days (tirzepatide) from intitiation of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
Report a problemFND-3957815603
03HumanObservational studySafety outcome
In FAERS tirzepatide reports, median time to impaired gastric emptying onset was 107.5 days after treatment initiation.
In plain wordsIn tirzepatide reports, impaired stomach emptying began a median of 107.5 days after treatment started.
Peptide
Tirzepatide
Outcome
Not applicableTime to impaired gastric emptying onset
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Median onset
107.5 days
tirzepatide
Source sentences
Summary
Median onset times ranged from 40.5 days (semaglutide) to 107.5 days (tirzepatide) from intitiation of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
Report a problemFND-3957815604

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Among reports for the top 10 drugs associated with impaired gastric emptying, five GLP-1RAs accounted for 49.5% (982/1982) of cases.
In plain wordsAmong reports for the top 10 implicated drugs, pooled GLP-1RAs accounted for 49.5% of impaired stomach emptying cases.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePooled GLP-1RA share of impaired gastric emptying reports
Study
n = 1,982
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
GLP-1RA report share
49.5%
top 10 drugs
GLP-1RA cases
982 reports
top 10 drugs
Source sentences
Summary
Among the top 10 drugs associated with IGE reports, five were GLP-1RAs, accounting for 49.5% (982/1982) of cases.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3957815608
05HumanNot a test of Semaglutide aloneObservational studySafety outcome
Among reports for the top 10 drugs associated with impaired gastric emptying, five GLP-1RAs accounted for 49.5% (982/1982) of cases.
In plain wordsAmong reports for the top 10 implicated drugs, pooled GLP-1RAs accounted for 49.5% of impaired stomach emptying cases.
Peptide
Semaglutide
Outcome
Not applicablePooled GLP-1RA share of impaired gastric emptying reports
Study
n = 1,982
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
GLP-1RA report share
49.5%
top 10 drugs
GLP-1RA cases
982 reports
top 10 drugs
Source sentences
Summary
Among the top 10 drugs associated with IGE reports, five were GLP-1RAs, accounting for 49.5% (982/1982) of cases.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3957815609
06HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Among reports for the top 10 drugs associated with impaired gastric emptying, five GLP-1RAs accounted for 49.5% (982/1982) of cases.
In plain wordsAmong reports for the top 10 implicated drugs, pooled GLP-1RAs accounted for 49.5% of impaired stomach emptying cases.
Peptide
Tirzepatide
Outcome
Not applicablePooled GLP-1RA share of impaired gastric emptying reports
Study
n = 1,982
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
GLP-1RA report share
49.5%
top 10 drugs
GLP-1RA cases
982 reports
top 10 drugs
Source sentences
Summary
Among the top 10 drugs associated with IGE reports, five were GLP-1RAs, accounting for 49.5% (982/1982) of cases.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3957815610
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In FAERS dulaglutide reports, older age was linked to lower odds of impaired gastric emptying.
In plain wordsIn dulaglutide reports, older age was linked to lower odds of impaired stomach emptying.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAge association with impaired gastric emptying
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Age odds ratio
0.97 ratio
dulaglutide
Lower confidence limit
0.94 ratio
95% CI
Upper confidence limit
1 ratio
95% CI
Source sentences
Summary
Dulaglutide (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.94-1.00, P=0.033) and semaglutide (OR 0.96, 95% CI 0.94-0.97, P=0.001) showed lower IGE risk with older age.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3957815601
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In FAERS reports, the Weibull shape parameter was below 1 for all GLP-1RAs, including dulaglutide, indicating higher impaired gastric emptying risk early in treatment.
In plain wordsIn reports for all GLP-1 drugs, including dulaglutide, the risk of impaired stomach emptying was higher early in treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTemporal impaired gastric emptying risk
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Weibull shape parameter
< 1 dimensionless
all GLP-1RAs
Source sentences
Summary
The Weibull shape parameter β was <1 for all GLP-1RAs, indicating a higher IGE risk early in treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3957815605
09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, the Weibull shape parameter was below 1 for all GLP-1RAs, including semaglutide, indicating higher impaired gastric emptying risk early in treatment.
In plain wordsIn reports for all GLP-1 drugs, including semaglutide, the risk of impaired stomach emptying was higher early in treatment.
Peptide
Semaglutide
Outcome
Not applicableTemporal impaired gastric emptying risk
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Weibull shape parameter
< 1 dimensionless
all GLP-1RAs
Source sentences
Summary
The Weibull shape parameter β was <1 for all GLP-1RAs, indicating a higher IGE risk early in treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3957815606
10HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, the Weibull shape parameter was below 1 for all GLP-1RAs, including tirzepatide, indicating higher impaired gastric emptying risk early in treatment.
In plain wordsIn reports for all GLP-1 drugs, including tirzepatide, the risk of impaired stomach emptying was higher early in treatment.
Peptide
Tirzepatide
Outcome
Not applicableTemporal impaired gastric emptying risk
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Weibull shape parameter
< 1 dimensionless
all GLP-1RAs
Source sentences
Summary
The Weibull shape parameter β was <1 for all GLP-1RAs, indicating a higher IGE risk early in treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3957815607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:07 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.